Next-generation sequencing (NGS)
Extend your spatial findings with NGS to validate targets, explore genomic alterations, and support biomarker discovery across tissue and liquid samples.
Spatial Omics and Transcriptomics Services
Turn spatial data into clinically relevant insight with integrated transcriptomic and proteomic analysis.
Unlock deeper biological insight with spatial omics
As translational and clinical research studies increasingly focus on heterogeneity and microenvironment-driven responses, combining molecular data with spatial context becomes essential – not only to generate clinically meaningful insights but also to better inform patient stratification, treatment strategies, and outcomes.
We support spatial omics applications across preclinical, translational, and clinical programs, delivering quantitative analysis of both proteins and transcripts from tissue samples. Our flexible workflows enable both bulk and spatially resolved approaches, targeting defined regions of interest or specific cell populations within tissue sections.
Our laboratories are equipped with NanoString™ nCounter® and GeoMx® platforms, allowing you to select the most appropriate approach based on your study objectives, sample type, and required level of spatial resolution.
We work with you to define study design, including region-of-interest selection and biomarker strategy. By combining histopathology, spatial technologies, and bioinformatics, we generate robust datasets that support confident decisions – and help move the right therapies closer to patients.
Core technology: NanoString™ nCounter®
The NanoString nCounter platform provides sensitive, multiplexed quantification of RNA and protein targets, making it well suited for both exploratory and translational studies across a wide range of sample types.
Key capabilities include:
- Broad applicability across preclinical and clinical studies, including human, mouse, and other species
- Direct digital detection of RNA and proteins using color-coded probe technology
- Compatibility with diverse sample types, including FFPE, frozen tissue, liquid biopsies, and cell samples
- Reliable performance with low-input and challenging samples such as FFPE or circulating RNA
- Access to ready-to-use panels covering multiple therapeutic areas, with options for custom probe and antibody design
- Quantification of up to 800 gene targets in a single assay
- Rapid wet lab turnaround times to support study timelines
Applications:
- Bulk RNA and protein profiling of fresh, FFPE, frozen, or liquid tumor samples
- Integration with complementary NGS-based panels for extended analysis
Core technology: NanoString™ GeoMx®
The NanoString GeoMx platform enables high‑plex spatial profiling of RNA and protein expression, allowing you to analyze molecular signatures within defined tissue regions while preserving morphological context.
Key capabilities include:
- High‑throughput spatial transcriptomic and proteomic profiling for clinical and preclinical studies
- Broad compatibility with sample types, including FFPE, fresh frozen tissue, whole mounts, TMAs, and biopsies
- Comprehensive coverage with up to 22,000+ genes and 150+ protein targets across human and mouse panels
- Flexible panel options, including whole transcriptome, cancer‑focused, and immune pathway panels
- Customizable assay design and morphology marker selection for targeted analysis
Spatial workflow support:
- Collaborative region of interest (ROI) selection with Cerba scientists, pathologists, and your team
- Alignment of stained slides to ensure consistent ROI transfer across workflows
- Integration with histopathology, IHC, and molecular data for deeper biological interpretation
Applications:
- Spatial RNA and protein profiling in FFPE and frozen tissue samples
- Characterization of tumor microenvironments and immune landscapes
- Support for biomarker discovery and translational research
Complementary technologies to extend your spatial insights
Spatial omics data becomes more valuable when combined with complementary molecular and analytical approaches. Our broader capabilities help you generate deeper insights and translate findings into clinical impact.
Assay development
Develop and validate custom assays to translate spatial insights into robust, scalable biomarkers for clinical development and regulatory use.
